

Supplementary tables for Part I of Boyce *et al* “A biomedical evidence taxonomy oriented toward confidence assignment”

Table 3: The distribution of evidence types among evidence items used to *support* drug mechanism assertions.

Qualitative assertion types						
Assertion type	Assertions	Defaults	Evidence Items	Percent of evidence items by type		
				clinical trial	in vitro	non-traceable
increases-auc	41	0	43	93	0	7
substrate-of	28	0	29	31	48	21
has-metabolite	20	0	27	19	37	44
controls-formation-of	16	0	17	0	94	6
primary-total-clearance-enzyme	12	4	12	58	0	42
inhibits	11	0	11	91	0	9
primary-total-clearance-mechanism	10	0	14	21	0	79
does-not-permanently-deactivate-catalytic-function ⁰	8	8	0	0	0	0
in-vitro-selective-inhibitor-of-enzyme	8	8	8	0	0	100
in-vitro-probe-substrate-of-enzyme	5	5	5	0	20	80
sole-PK-effect-alter-metabolic-clearance	5	5	0	0	0	0
polymorphic-enzyme	4	4	0	0	0	0
in-viVo-selective-inhibitor-of-enzyme	4	4	4	0	0	100
primary-metabolic-clearance-enzyme	3	0	3	0	33	67
permanently-deactivates-catalytic-function ⁰	1	1	1	0	100	0
Total	176	39	174			

Quantitative assertion types						
Assertion type	Assertions	Defaults	Evidence Items	Percent of evidence items by type		
				clinical trial	in vitro	non-traceable
maximum-concentration	11	0	24	67	0	33
inhibition-constant	9	0	15	0	100	0
bioavailability	8	0	13	38	0	62
fraction-absorbed	2	0	2	100	0	0
first-pass-effect	1	0	1	0	0	100
Total	31	0	55			

⁰ The inverse assertions `permanently-deactivates-catalytic-function` and `does-not-permanently-deactivate-catalytic-function` do not share any of the same evidence items so are included in the analysis

Table 4: The distribution of evidence types among evidence items used to *refute* drug mechanism assertions.

Qualitative assertion types						
Assertion type	Assertions	Defaults	Evidence Items	Percent of evidence items by type		
				clinical trial	in vitro	non-traceable
increases-auc	41	0	12	75	0	25
substrate-of	28	0	11	0	91	9
has-metabolite	20	0	0	0	0	0
controls-formation-of	16	0	0	0	0	0
primary-total-clearance-enzyme	12	4	0	0	0	0
inhibits	11	0	4	50	50	0
primary-total-clearance-mechanism	10	0	0	0	0	0
does-not-permanently-deactivate-catalytic-function ⁰	8	8	0	0	0	0
in-vitro-selective-inhibitor-of-enzyme	8	8	0	0	0	0
in-vitro-probe-substrate-of-enzyme	5	5	0	0	0	0
sole-PK-effect-alter-metabolic-clearance	5	5	0	0	0	0
polymorphic-enzyme	4	4	0	0	0	0
in-viVo-selective-inhibitor-of-enzyme	4	4	0	0	0	0
primary-metabolic-clearance-enzyme	3	0	1	100	0	0
permanently-deactivates-catalytic-function ⁰	1	1	0	0	0	0
Total	176	39	28			

Quantitative assertion types						
Assertion type	Assertions	Defaults	Evidence Items	Percent of evidence items by type		
				clinical trial	in vitro	non-traceable
maximum-concentration	11	0	0	0	0	0
inhibition-constant	9	0	0	0	0	0
bioavailability	8	0	0	0	0	0
fraction-absorbed	2	0	0	0	0	0
first-pass-effect	1	0	0	0	0	0
Total	31	0	0			

⁰ The inverse assertions `permanently-deactivates-catalytic-function` and `does-not-permanently-deactivate-catalytic-function` do not share any of the same evidence items so are included in the analysis